Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) announced the successful acquisition of LiDCO Group Plc, a prominent provider of hemodynamic monitoring solutions, on February 2, 2021. This strategic acquisition involves 100% ownership of LiDCO, which was previously listed on the London Stock Exchange's AIM submarket. Founded in 1991, LiDCO specializes in noninvasive hemodynamic monitoring equipment, focusing on optimizing patient care and outcomes. As a newly formed private subsidiary, LiDCO aims to leverage Masimo's advanced healthcare technologies to enhance patient monitoring capabilities.

Masimo (NASDAQ: MASI) has launched iSirona™, a connectivity hub that enhances interoperability in medical settings. The hub connects up to six devices, routing data to the Masimo Hospital Automation™ platform for effective EMR integration and monitoring. Compatible with over 500 medical devices, iSirona minimizes manual charting and transcription errors, streamlining clinician access to patient data. Its compact design suits space-constrained areas like operating rooms, and an onboard battery ensures data continuity during power outages.

Masimo Corporation (Nasdaq: MASI) reported preliminary financial results for 2020, expecting product revenue between $1.139 billion and $1.144 billion, representing growth of 21.6% to 22.2%. The company anticipates GAAP earnings per diluted share exceeding $3.77 and non-GAAP earnings exceeding $3.46. For 2021, Masimo projects product revenue of $1.200 billion, marking growth of 4.9% to 5.4%. The recent acquisition of LiDCO may contribute 1% to 2021 revenue growth, although it may slightly dilute non-GAAP earnings.

Masimo (NASDAQ: MASI) is collaborating with Renown Health in Reno, Nevada, to address the COVID-19 surge through the use of Masimo SafetyNet, a remote patient management platform. This technology supports home recovery for COVID-19 patients while enabling clinicians to monitor their conditions remotely. Renown Health employs Masimo's advanced monitoring solutions to enhance patient care and mitigate hospital congestion during the pandemic. Masimo SafetyNet combines noninvasive monitoring tools to ensure timely interventions, ultimately improving patient outcomes and reducing healthcare costs.

Masimo (NASDAQ: MASI) revealed findings from a study presented at Euroanaesthesia 2020, led by Dr. Kumagai at Iwate Medical University. The research demonstrated that Masimo ORi™, or Oxygen Reserve Index, effectively limits postoperative hyperoxia, potentially preventing hypoxia. In a trial involving 50 breast surgery patients, those monitored with ORi had significantly lower arterial oxygen levels post-surgery compared to a control group. However, ORi is currently not available in the U.S. due to the lack of FDA 510(k) clearance.

Masimo (NASDAQ: MASI) presented findings at Euroanaesthesia 2020, revealing that its noninvasive hemoglobin monitoring technology, SpHb, significantly improved outcomes in pediatric patients undergoing major surgeries. The study indicated a reduced rate of postoperative transfusions, shorter ICU stays, and decreased morbidity compared to traditional methods. Key metrics showed a 40% reduction in ICU stay durations and a 43% decrease in postoperative red blood cell transfusions. These results highlight SpHb's potential for better patient care and cost-effectiveness in transfusion management.

Masimo (NASDAQ: MASI) was recognized as one of seven innovators at California Life Sciences Association's Pantheon 2020 for its role in addressing COVID-19 challenges. The company's Masimo SafetyNet platform supports remote patient monitoring, enabling clinicians to track patients' health metrics from home, thus alleviating hospital strain. Mike Guerra from CLSA praised Masimo's adaptability during the pandemic. CEO Joe Kiani acknowledged the frontline healthcare workers' contributions and highlighted the impact of their technology in improving patient outcomes.

Masimo (NASDAQ: MASI) announces participation in the Piper Sandler Virtual Healthcare Conference on December 2, 2020, at 3:30 p.m. ET. The live presentation will be webcast on the Masimo website, with a replay available afterward. Masimo is recognized for its innovative medical monitoring technologies aimed at improving patient outcomes and reducing healthcare costs. Notably, Masimo SET® pulse oximetry is employed in over 100 million patients globally, with advancements enhancing its accuracy under various conditions.

Masimo (NASDAQ: MASI) announced a study published in the Ain-Shams Journal of Anesthesiology, highlighting the effectiveness of its PVi technology for assessing fluid responsiveness in mechanically ventilated patients. Conducted at Ain-Shams University, the study found PVi to be more reliable and continuous compared to dIVC, with significant results showing PVi's reliability (93.75% sensitivity) against an invasive method. These findings support PVi's potential in improving patient care in surgical ICU settings.